Bristol-myers Squibb Compnay

Eastman-kodak Company

F Christopher Zusi

John E Macor

Richard Eric Olson

Ivar M McDonald

James H Cook, Ii

Dalton King

Christiana I Iwuagwu

Nenghui Wang

Matthew D Hill

Robert A Mate

Haiquan Fang

Alaric J Dyckman

William John Pitts

Makonen Belema

Joanne J Bronson

Steven H Spergel

Min Ding

Neil F Haley

Yuping Qiu

Jianliang Shi

Lawrence R Marcin

Lorin A Thompson, Iii

Patrice Gill

Alison B Lukacsko

Kenneth M Tramposch

Mendi A Higgins

James Kempson

Gerard J Gendimenico

Ivar M Mcdonald

Rex Denton

Michael D Helman

Xina Nair

Claude Quesnelle

Thomas A Re

R Thomas Swann

William Somerville

Suresh Marathe

Kimberley A Lentz

Michael F Dee

James H Cook Ii

James H Ii Cook

There are disclosed a series of quinuclidines having the Formula (I), which bind to the nicotinic &#x3b1;7 receptor and may be useful for the treatment of disorders of the central nervous system. 

Quinuclidine compounds as &#x3b1;-7 nicotinic acetylcholine receptor ligands

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders

The disclosure provides compounds of formula I including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, and Ras defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by &#x3b2;-secretase and, more specifically, inhibit the production of&#x3b2;-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to &#x3b2;-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Indole acetic acid acyl guanidines as &#x3b2;-secretase inhibitors

The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R, R, R, and Rare as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

[object Object]

New compounds (3-alkyl-5-hydroxy-3,4-dihydrofuran-2-ones) of the following general structure: ##STR1## wherein R is an alkyl group or a phenylalkyl group with the alkyl moiety containing at least 6 carbon atoms, are disclosed as useful in inhibiting phospholipase A.sub.2.

Furanone anti-inflammatory agents

The present invention provides for a composition containing a pharmacologically active agent and a selected imidazole or an imidazole derivative, such composition exhibiting enhanced penetration of the pharmacologically active agent component when a composition containing the aforementioned components is applied to skin. A method of enhancing dermal penetration of compositions containing a pharmacologically active agent is also provided.

Method for enhancing transdermal penetration and compositions useful

The effects of acne and psoriasis are relived by applying either topically or by oral adminstration, a compound having the structure: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from the group consisting of H, Cl, straight or branched alkyl of 1 to 10 carbon atoms, NO.sub.2, COOR.sub.6, CN, OR.sub.6, NR.sub.6 R.sub.7, NR.sub.6 C(.dbd.S)NR.sub.7 R.sub.8, NF.sub.6 COR.sub.7, SO.sub.2 NR.sub.6 R.sub.7, CH(CH.sub.3)COOH, CONR.sub.6 R.sub.7, COR.sub.6, OCONR.sub.6 R.sub.7, NR.sub.6 COONR.sub.7, R.sub.9 OR.sub.6, NR.sub.6 SO.sub.2 R.sub.7, Si(CH.sub.3).sub.3, and NR.sub.6 CONR.sub.7 R.sub.8,

Compound and method for treating skin for acne or psoriasis

Growing community of inventors

Hamden, CT, United States of America

F Christopher Zusi